Novavax today announced that the Standing Committee on Vaccination (STIKO) in Germany has expanded its recommendations for use of Nuvaxovid™(NVX-CoV2373) as a COVID-19 booster.
STIKO recommends Nuvaxovid as a booster among adults aged 18 and older that have product-specific medical contraindications to mRNA COVID-19 vaccines or request Nuvaxovid after appropriate consultation. STIKO specifies that Nuvaxovid can be administered at intervals of at least six months after a previous immunological event (infection or vaccination). STIKO also recommends Nuvaxovid for off-label use as a booster in adolescents aged 12 through 17 that have product-specific medical contraindications for mRNA COVID-19 vaccines.
Nuvaxovid’s breadth of immune response following boosting has been demonstrated in a number of trials including Novavax' Phase 2 trial in the U.S. and Australia, the PREVENT-19 trial, the Phase 3 COVID-19 Omicron trial, and the U.K.-sponsored COV-BOOST trial. These data have shown the vaccine can induce a functional immune response against circulating Omicron subvariants and that the immune response to these subvariants increases with subsequent boosting.
Novavax’ COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries, and a number of other countries have policy recommendations allowing use of the vaccine as a booster dose.
Trade Name in the U.S.
The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.
For more information on the use of Nuvaxovid, please visit https://de.novavaxcovidvaccine.com/hcp